1	High proportion of genome-wide homology and increased basal pvcrt levels in
2	Plasmodium vivax late recurrences: a chloroquine therapeutic efficacy study
3	
4	Eduard Rovira-Vallbona ¹ #, Nguyen Van Hong ² , Johanna H. Kattenberg ¹ , Ro Mah Huan ³ ,
5	Nguyen Thi Huong Binh ² , Nguyen Thi Hong Ngọc ² , Pieter Guetens ¹ , Nguyen Luong Hieu ² ,
6	Nguyen Thị Thu Hien ² , Vu Thi Sang ² , Nguyen Duc Long ² , Erin Sauve ¹ , Tran Thanh Duong ² ,
7	Nguyen Xuan Xa ² , Annette Erhart ^{1,4} , Anna Rosanas-Urgell ¹ #
8	
9	¹ Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
10	² National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam.
11	³ Centre for Disease Control and Prevention, Gia Lai, Vietnam.
12	⁴ Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical
13	Medicine, Fajara, The Gambia.
14	
15	Running Head: Efficacy of CQ against P.vivax in Central Vietnam
16	
17	#Address correspondence to Anna Rosanas-Urgell, arosanas@itg.be; Eduard Rovira-
18	Vallbona, <u>edu.rovira@outlook.com</u>
19	

20 E.R.V. and N.V.H. contributed equally to this work.

21 ABSTRACT

22

Chloroquine (CQ) is the first-line treatment for *Plasmodium vivax* malaria in most endemic 23 countries. Monitoring *P.vivax* CO resistance (COR) is critical but remains challenged by the 24 25 difficulty to distinguish real treatment failure from reinfection or liver relapse. Therapeutic efficacy of CO against uncomplicated *P.vivax* malaria was evaluated in Gia Lai province, 26 27 Vietnam. Sixty-seven patients were enrolled and followed-up for 42 days using microscopy 28 and (RT)qPCR. Adequate clinical and parasitological response (ACPR) was 100% (66/66) on Day 28, but 75.4% (49/65) on Day 42. Eighteen recurrences (27.7%) were detected with 29 30 a median time-to-recurrence of 42 days (IQR 35, 42) and blood CQ concentration <100ng/ml. Parasite genotyping by microsatellites, SNP-barcoding and whole-genome sequencing 31 32 (WGS) identified a majority of homologous recurrences, with 80% (8/10) showing >98% identity-by-descent to paired Day 0 samples. Primary infections leading to recurrence 33 occurred in younger individuals (median age for ACPR=25 years [IQR 20, 28]; 34 recurrences=18 [16, 21]; p=0.002), had a longer parasite clearance time (PCT for 35 ACPR=47.5h [IQR 36.2, 59.8]; recurrences=54.2h [48.4, 62.0]; p=0.035) and higher pvcrt 36 gene expression (median relative expression ratio for ACPR=0.09 [IQR 0.05, 0.22]; 37 38 recurrences=0.20 [0.15, 0.56]; p=0.002), but there was no difference in ex vivo CQ sensitivity. This study shows that CQ remained largely efficacious to treat *P.vivax* in Gia Lai, 39 40 *i.e.* recurrences occurred late (>Day 28) and in the presence of low blood CQ concentrations. However, the combination of WGS and gene expression analysis (pvcrt) with clinical data 41 (PCT) allowed to identify potential emergence of low-grade CQR that should be closely 42 monitored. 43

44

45 INTRODUCTION

46

47 Plasmodium vivax was responsible for 6.4 million malaria cases globally according to the World Health Organization (WHO) estimates for 2019, with most of them occurring in Asia 48 (1). Historically mistaken as benign, P. vivax is becoming the predominant malaria species 49 50 in countries where the incidence of *Plasmodium falciparum* is decreasing as they are moving towards malaria elimination (2). Whereas addressing asymptomatic infections and drug 51 resistance are cross-cutting issues in the elimination of both P. vivax and P. falciparum, the 52 treatment and control of *P. vivax* present additional unique challenges due to key biological 53 differences, such as the presence of liver hypnozoites responsible for relapses (i.e. 54 55 reactivation of dormant parasite forms leading to blood-stage infection), the low parasite 56 density in peripheral blood, and the production of gametocytes (*i.e.* parasite transmissible stages) before the onset of symptoms (2,3). 57

58

Chloroquine (CQ) is the first-line drug treatment for *P. vivax* in most endemic countries (1). 59 60 Chloroquine resistance (CQR) in malaria parasites emerged first in *P.falciparum* shortly after the start of widespread use as an antimalarial treatment in the 1950s (4). The first report of 61 P. vivax CQR emerged 30 years later in Papua New Guinea and, since then, decreasing 62 efficacy of CO against P. vivax has been reported across malaria endemic areas around the 63 world, although with different degrees of certainty (3,4). In countries where high level CQR 64 has been confirmed (i.e. Papua New Guinea, Indonesia and Malaysia) artemisinin-based 65 66 combination therapies have been adopted as the universal antimalarial first-line treatment instead of CQ (1,4). 67

68 In order to evaluate the efficacy of CO regimens against P. vivax, the WHO recommends to 69 conduct therapeutic efficacy studies (TES) with at least 28 days of patient follow-up after 70 treatment administration (5). Recurrences within this period with a confirmed CQ blood 71 concentration over the minimum effective concentration (MEC) of 100 ng/ml would support the presence of CQR. However, it has also been shown that a long-acting antimalarial drug 72 like CO can linger in the bloodstream for approximately 35 days and delay appearance of 73 74 relapses up to six weeks (6,7). Extended follow-up periods of 42 or 63 days are therefore recommended to detect recurrences with parasites at early stage of COR (5,8). Nonetheless, 75 76 a main challenge of *P. vivax* TES studies is to distinguish a parasite recrudescence caused by 77 real treatment failure from a relapse or new infection, for which additional ex vivo and in vitro laboratory tests are required (8). On one hand, genotyping of parasites at polymorphic 78 79 genome regions can show whether recurrent parasite clones differ from those in the initial infection -especially when using high-resolution approaches at whole-genome level (9,10)-80 81 but if applied alone they remain limited to unambiguously differentiate a recrudescence from 82 a genetically homologous relapse. On the other hand, short-term ex vivo cultures of isolates exposed to CQ and genotyping of drug resistance markers can be combined to characterize 83 isolates CQR properties. 84

The identification and validation of CQR markers in *P. vivax* has unfortunately been hampered by the inability to long-term culture the parasite and evaluate adaptation to extended drug-exposure (11). Despite this limitation, numerous studies have linked CQR to both chloroquine resistance transporter (*pvcrt*) and multidrug resistance gene-1 (*pvmdr*1) genes. Associations with SNPs and/or copy number variation in both *pvcrt* and *pvmdr1* have remained weak and sometimes contradictory (12–16). At the transcriptional level, increased expression of *pvcrt* and *pvmdr1* was found in CQR infections from the Brazilian Amazon

92 (17), whereas *pvcrt* expression was upregulated in a genetic cross of *P. vivax* parasites
93 differing in their CQ response in experimental non-human primate infections (18).

94

In Vietnam, P. vivax accounts for 40% of all malaria cases, which occur mainly among ethnic 95 minorities in forested areas in central and southern provinces (19). National guidelines for 96 97 the treatment of P. vivax infection follows WHO recommendation of 3 days of CQ (25 98 mg/kg) followed by 14 days of primaquine (PQ; 0.25 mg/kg) radical-cure treatment to eliminate liver hypnozoites. To date, only one study conducted in Quang Nam province 99 (Central Highlands) between 2009-2011 confirmed P. vivax CQR by reporting a 3.5% failure 100 101 rate (n=8) at Day 28 and three cases with CQ blood concentrations >100ng/ml, although no genetic analysis of recurrences were performed (20). A few other reports d of suspected P. 102 103 vivax CQR have been published in the last twenty years in Binh Thuan, Binh Phuoc and Ninh Thuan provinces (recurrence rates at Day 28 or later ranging 13%-57%), but CQR could not 104 105 be confirmed due to the lack of either blood CQ levels or genotyping of recurrent infections 106 (21)(22)(23).

107

In the present study we assessed the *in vivo* susceptibility of *P. vivax* to CQ in Gia Lai (Central Vietnam), the province with the highest malaria burden in the country in recent years (19,24). We used good manufacturing practice certified CQ and administered the currently recommended radical cure regimen of PQ at the end of the 42 days of follow-up. Importantly, we provide a thorough analysis of treatment failures by combining *ex vivo* drug sensitivity assays, three technical approaches to genetic analysis of recurrences, as well as genotyping of candidate markers of drug-resistance including gene expression analysis.

115

116 MATERIALS AND METHODS

117

118 Study site

The study was conducted between May 2015 and February 2017 in Chu R'Cam commune's 119 120 health center (CHC), Krong Pa district (Gia Lai province, Central Highlands, Vietnam), where a small field laboratory was set-up. In addition, CHC in the nearby communes of Ia 121 122 R'Sai, Ia R'Suom and Uar were asked to refer all potentially eligible patients to the reference CHC. Chu R'Cam is located 120 km south-east of the provincial capital Pleiku, next to the 123 Ba river in a large valley surrounded by hilly and partially forested areas (25). The local 124 125 population is mainly from J'Rai ethnic minority, which has in general a low socio-economic status and education level. Local housing structures consist of government supported brick 126 127 or wooden houses built on concrete floors. The main occupation is slash-and burn agriculture in forest fields, which often requires sleeping in the forest. The climate is tropical, with the 128 dry season from November to April and the rainy season from May to October. Malaria 129 transmission usually begins in May and peaks from September to December, with the lowest 130 incidence between February and April. At the time of study initiation in 2015, Gia Lai 131 province had reported 4367 microscopically confirmed malaria cases, the highest burden in 132 133 the country, of which 1051 P. falciparum and 1124 P. vivax occurred in Krong Pa district (19,24). Malaria control by the provincial malaria station relies on early diagnosis by light 134 microscopy (LM) or rapid diagnostic tests, annual distribution of long-lasting insecticidal 135 136 treated nets, promotion of community-based prevention behavior and monitoring of drug resistance through regular TES. The presence of *P. falciparum* artemisinin resistance was 137 confirmed in the province in 2017 (25). 138

139

140 Study design and trial procedures

141 The study was designed as a 42-day drug efficacy study to evaluate clinical and parasitological responses after treatment of P. vivax uncomplicated malaria infections. 142 Patients aged >1 year-old presenting to the CHC with fever (> 37.5° C) and/or history of 143 144 fever during the previous 48 hours were screened for malaria infection by blood smears from finger prick, and hemoglobin (Hb) concentration was measured using Hb201+ System 145 146 (Hemocue). Those with LM confirmed *P. vivax* mono-infection and asexual parasite density >250 parasites/µl were invited to enroll and provide written informed consent. Individuals 147 148 diagnosed with P. falciparum or mixed infections, signs of severe malaria, febrile diseases 149 other than malaria, or any chronic medical condition, as well as pregnant and breastfeeding women, were excluded. Prior to treatment, 5 ml of whole blood was collected by 150 venepuncture for nucleic acid purification and ex vivo drug assays (200µl were transferred 151 into an EDTA microtainer, 100 µl were transferred into an RNAprotect-containing 152 containing tube and stored at -20°C, and remaining blood was processed as described below). 153 After treatment initiation patients remained in the health center where they were monitored 154 by LM every 12 hours for 72 hours (Day 3) or until parasite clearance was confirmed by two 155 consecutive LM negative slides. On Days 7, 14, 28, 35 and 42 patients were asked to return 156 157 for follow-up visits or were visited at home by health centre staff. At each visit, a finger prick was conducted to prepare thick and thin smears, 200µl of blood was transferred into an EDTA 158 159 microtainer (for DNA extraction), and another 100µl was transferred into an RNAprotect-160 containing tube (for RNA extraction). On Day 7, 100µl of blood were collected onto chromatography paper for drug concentration measurements (31ETCHR, Whatman). Hb 161 levels were measured on Days 14, 28, and 42. In case of confirmed recurrence, a 5ml venous 162 blood sample and a blood spot on chromatography paper were collected prior to rescue 163

treatment administration. A system of passive detection of fever cases was maintainedthroughout the study period.

166

167 **Treatment**

All patients received a full treatment with CQ (Nivaquine®, Sanofi) at a total dose of 25mg 168 of CO base/kg body weight, given over 3 days and under direct observation (10mg the first 169 170 two days and 5mg on the third)(26). Exact dosage given per patient was registered on case 171 report forms. Individuals who vomited their medication within the first 30 minutes after 172 treatment received another full dose, whereas those vomiting between 30 and 60 minutes 173 after treatment received another half dose. The time when patients received the first dose was defined as Day 0. PQ (0.25mg/kg/day for 14 days, Sanofi/Valeant Pharmaceuticals) was 174 given at the end of follow-up on Day 42 to all patients testing negative for glucose-6-175 phosphate dehydrogenase deficiency (G6PD; CareStart, Access Bio) under supervision of 176 health workers. Patients with recurrences at Day 42 or earlier were administered radical cure 177 treatment as per national guidelines, consisting of CQ (25mg/kg, 3 days) together with PQ 178 179 (0.25 mg/kg/day for 14 days)(26).

180

181 Microscopy

Malaria diagnosis by LM was conducted by examining thick and thin smears stained with freshly prepared 10% Giemsa for 15 min under 1000X magnification. Parasite density was calculated by counting the number of asexual parasites per 200 white blood cells (WBC) with a hand tally counter and expressed as parasites/ μ l of blood assuming a WBC density of 8000 cells per μ l. Blood smears were considered negative when no asexual parasites were found after counting 1000 WBC. All smears were read in duplicate by two trained microscopists

and the final density was expressed as the average result. A third reading was conducted by
another technician in case of discrepancy in positivity, species diagnosis, or parasite count
by >25%. Fifteen per cent randomly selected blood smears were sent to ITM (Antwerp,
Belgium) for external quality control.

192

193 *P. vivax* quantification by (RT)qPCR

194 DNA was extracted from 200 µl whole blood in EDTA using Favorprep 96-well Genomic DNA kit (Favorgen) and eluted in 200 µl of water. Duplex qPCR targeting P. vivax and P. 195 196 falciparum 18S ribosomal RNA genes was performed in samples from Day 0 using TaqMan 197 Universal Master Mix II and StepOne Plus Real-Time PCR System (Applied Biosystems) 198 (27). The same method was adapted as a *P. vivax* monoplex qPCR and used for *P. vivax* 199 quantification in follow-up samples. RNA was extracted from RNAprotect samples collected at Day 0 and from all follow-up samples positive in the *pv18S rRNA* qPCR, using RNeasy 200 Plus 96- kit (Qiagen) (25). Final RNA elution was conducted in 100 µl of RNAse-free water, 201 and the presence of quality RNA was confirmed in a random selection of 80 samples by one-202 step reverse transcription qPCR (RTqPCR) targeting pv18S rRNA transcripts, using 203 LightCycler Multiplex RNA Virus Master mix in a LightCycler480 thermocycler (Roche). 204 205 The presence of *P. vivax* stage V gametocytes was determined by RTqPCR amplification of pvs25 RNAs (28). A standard curve (10⁶-1 copies/µl) of plasmids containing the pvs25 PCR 206 207 fragment was included in each plate for copy number quantification (28).

208

209 *Ex vivo* schizont maturation assays (SMA)

210 Venous blood vacutainers were centrifuged, and plasma and buffy coat stored at -20°C.

211 Infected red blood cells (iRBC) were diluted to 25% haematocrit in sterile PBS and passed

212 through an autoclaved 10ml syringe (Terumo, SS10LE1) prefilled with cellulose powder 213 2.5ml-layer (Sigma-Aldrich, C6288) on top of a lens-cleaning paper to remove white blood cells. In all samples with a ring-stage proportion >65%, 150 µl iRBC were separated for ex 214 215 vivo drug sensitivity SMA and remaining iRBC pellet was cryopreserved in liquid nitrogen 216 or stored at -20°C. SMA was performed by adapting WHO microtest, as previously described 217 (25,29). A stock solution of 640µM CQ in water (Sigma-Aldrich, C6628) was pre-dosed in 218 seven 2-fold serial dilutions in water (800-12.5nM), and 25 µl/well were distributed in a 96well plate, air-dried overnight inside a laminar-flow cabinet and stored at 4°C (30). The 150µl 219 220 iRBC were resuspended to 2% hematocrit in pre-warmed McCoy's 5A medium (Gibco) supplemented with 20% human serum (non-exposed Vietnamese individuals), and 200 221 222 µl/well of the iRBC-medium mixture were added to pre-dosed plates, including drug-free 223 wells. Plates were cultured at 37°C and drug-free wells monitored by LM at 34h, and 224 thereafter every 2-4h until the number of schizonts reached 40% (or until 42 hours). The 225 percentage of schizonts per each drug concentration was determined by double-reading of 226 blood smears and result expressed as schizonts % relative to the drug-free well. Half maximal 227 inhibitory concentrations (IC50) were calculated using WWARN's online In Vitro Analysis 228 and Reporting Tool (31).

229

230 **Drug concentration in blood**

Concentrations of CQ and desethyl-chloroquine (DCQ, *i.e.* the main chloroquine metabolite)
were measured in paired samples on Day 7 and Day of recurrence (DRec). Blood expelled
onto chromatography papers was air dried and stored in separate plastic bags with silica gel.
Drug measurements were conducted by liquid chromatography–mass spectrometry at the
Department of Clinical Pharmacology, Mahidol-Oxford Tropical Medicine Research Unit

(Bangkok, Thailand). The minimum effective concentration (MEC) was considered a
[CQ]+[DCQ] value of 100 ng/ml (8).

238

239 Microsatellites genotyping

240 Paired Day 0 and DRec samples were genotyped at polymorphic markers Pvmsp1F3, MS4, 241 MS10 and PvSal1814, selected based on the high degree of heterozygosity found in Central 242 Vietnam and adapting previously published protocols (see Table S1) (32) (33,34). All 243 products were run on a 2% agarose gel, and 20µl pool of Pvmsp1F3 (5µl), MS4 (7.5µl) and 244 MS10 (7.5 µl) PCR products and PvSal1814 products were sent off for capillary 245 electrophoresis at Genoscreen (Lille, France). Allele calling was performed using GeneTools (Syngene) and GeneMarker v2.4.0 (Softgenetics). All samples were double-checked 246 247 manually and the predominant allele (*i.e.* the highest peak) and minor alleles within at least two-thirds of the height of the predominant allele were scored. Alleles were considered 248 identical if size difference was ≤ 2 bp. Complexity of infection (COI; *i.e.* the estimated 249 250 number of genetically distinct clones within an infection) was defined as the highest number of alleles found in any of the four markers. Genotypes at Day 0 and DRec were classified as 251 252 homologous (when all or some of the alleles present in Day 0 sample were found in DRec 253 sample for all markers), heterologous (when none of the alleles present in Day 0 sample were 254 found at DRec for at least one marker), or indeterminate (when no amplification was achieved 255 for any marker).

256

257 SNP barcode

A molecular barcode consisting of 38 SNPs across the *P. vivax* genome was used to genotype
samples in the context of MalariaGEN SpotMalaria Project (Welcome Sanger Institute,

Hinxton, UK), using MALDI-TOF mass spectrometry of PCR amplicons in a
MassARRAY® System (Agena BioScience) (25)(35). Nucleotide sequence results were
provided in the form of a Genetic Report Card (see Data S1). Recurrences were classified as
homologous to Day 0 if there were no nucleotide differences in any non-heterozygous
position of the barcode, irrespective of the total number of successfully genotyped SNPs.

265

266 Whole-genome sequencing

DNA was initially subject to selective whole-genome amplification (sWGA) with phi29 267 268 DNA polymerase (New England Biolabs) according to previously published methodology 269 $(30 \ \mu l \text{ of DNA in } 50 \ \mu l \text{ reaction volume})(36)$. Product was purified with AMPure XP beads (Beckman-Coulter) and 15µl were used in a second sWGA round (50 µl reaction volume). 270 271 Final sWGA purified product concentration was determined in a Qubit 2.0 Fluorometer (Life 272 Technologies), and a minimum of 1mg was sent to BGI (Hong Kong) for library preparation 273 and 150bp paired-end WGS on a HiSeq X Ten (Illumina). FASTQ files were trimmed using 274 Trimmomatic to remove adapters and low quality reads, and aligned to the reference genome PvP01 using the BWA-MEM algorithm v0.7.17 (37). Variants were called using 275 HaplotypeCaller in GVCF mode followed by Joint-Call Cohort (GATK 4.1.2.0, Broad 276 277 Institute) and filtered to include only biallelic SNPs in the core genome, MQ>50, QUAL>30 278 and combined DP \geq 100, resulting in 191849 high quality SNPs (38). Samples with at least 279 10X coverage were kept for subsequent analysis (see Table S2). Within-host infection 280 complexity was assessed using within-sample F statistic (FWS) and FWS>0.95 was considered as a proxy for a monoclonal infection (39,40). Pairwise comparisons between all 281 samples were analysed in as identity-by-state (IBS) and identity-by-descent (IBD). For the 282 IBS approach, the proportion of discordant SNPs was determined by calculating the Prevosti 283

12

284 distance (*i.e.* number of allelic differences/number of possible differences). Distance was 285 fitted as the sum of four Gaussian distributions and the mean of the lowest distribution was set as the threshold for IBS-homologous recurrence (see Fig S1). For the IBD analysis, PED 286 287 and MAP file formats were created from using VCFtools and the proportion of the genome IBD between pairs of samples was calculated using isoRelate R package (41). Genetic 288 289 distance was calculated using estimated mean map unit size from P. chabaudi chabaudi of 290 13.7 kb/cM (42). We set thresholds of IBD on the minimum number of SNPs (20) and length 291 of IBD segments (50.000) reported to reduce false positive calls. Pairwise comparisons with 292 \geq 95% of their genome identical-by-descent were considered homologous and all pairwise 293 comparisons with shared IBD <95% were considered heterologous.

294

295 Molecular markers of drug resistance

Gene expression of *pvcrt* and *pvmdr1* were determined directly on RNA samples by one-step 296 297 RTqPCR. β -tubulin was used as reference gene. Each 10µl reaction volume contained 2µl of 298 LightCycler EvoScript RNA SYBR Green I Master (Roche), 0.4µM of forward and reverse primers (from ref. (17)), and 2.5µl of RNA template. LightCycler480 (Roche) thermal 299 cycling conditions were 60°C for 15 minutes, 95°C for 10 minutes, 45 cycles of 95°C for 10 300 301 seconds and 58°C for 30 seconds, followed by a melting curve step to ensure amplification 302 specificity. Samples were run in triplicate and excluded from calculations if final SD of 303 duplicates after removal of outliers was >0.4. Gene expression was estimated using the 304 efficiency-adapted Pfaffl relative quantification model (43), in which the relative expression 305 ratio (R) is calculated as the efficiency of the target genes (see Fig S2) raised to the power of 306 the Ct difference between a given sample and a control (*i.e.* mean Ct + 2*SD of all Day 0 samples with ACPR), and divided by the same formula applied to reference gene β -tubulin. 307

Mutations in *pvmdr1* codons 976 ($Y \rightarrow F$) and 1076 ($F \rightarrow L$) were genotyped by nested PCR amplification using primers from *Golassa et al* (primary) and *Lin et al* (nested; see Table S1) (44,45). The 646bp amplification products were sequenced at Genoscreen (Lille, France). Nucleotide sequences (Genbank accession numbers MW245736-MW245808) were entered to BioEdit 7.0 and aligned using ClustalW with default parameters.

313

314 Clinical trial endpoints

The primary endpoint was adequate clinical and parasitological response (ACPR) at 28 and 315 316 42 days of follow-up. Treatment failures were classified as early treatment failure, late 317 clinical failure (LCF, *i.e.* parasitemia with fever or signs of severe malaria between Day 4 and Day 42) or late parasitological failure (LPF, *i.e.* parasitemia between Day 7 and Day 42), 318 based on WHO guidelines (5). Patients who discontinued due to reappearance of parasites 319 and subsequent rescue treatment were considered evaluable for Day 42 endpoint analysis. 320 321 Secondary endpoints were parasite clearance estimates obtained from the log_e parasitemia-322 time LM data entered into WWARN Parasite Clearance Estimator (46), asexual and sexual 323 parasite carriage on Day 0-3 and during follow-up (including submicroscopic) and severe anemia (Hb<7g/dl) on Day 7. 324

325

326 Statistical analysis

For sample size calculation, the initial estimation of 5% treatment failure rate (based on the Quang Nam study (20)) was amended to 20% upon completion of the first year of the study, after observing treatment outcome results together and an extremely low malaria incidence in the district. To detect a minimum failure rate of 20%, a minimum sample size of 61 patients was necessary (10% precision and 95% confidence level), which was extended to 67 to allow

332 for 10% loss to follow-up. All clinical data were double entered into a Microsoft Access 333 database and transferred to Stata v11.0. The primary study outcomes were analysed using 334 both *per-protocol* and intention-to-treat (ITT) patient population. Comparisons between groups for continuous variables were performed using Wilcoxon rank-sum test and 335 336 proportions were compared using Chi-square or Fisher's exact tests, when appropriate. 337 Correlation between variables was assessed by Spearman's test. Clearance time for total 338 parasites and for gametocytes was estimated using Kaplan-Meier survival curves and 339 comparisons between subgroups were done using log-rank test. Time was computed in hours 340 and since treatment administration. Gene expression data was log-transformed, and 341 comparisons between groups were performed by pairwise Wilcoxon rank-sum test, with Benjamini & Hochberg correction in cases of multiple testing. A linear model adjusted for 342 343 the proportion of ring-stage parasites was applied to investigate the potential effect of stage composition on gene expression (47). Paired analyses between Day 0 and DRec were done 344 345 using Wilcoxon matched-pairs signed-rank test. Statistical analysis and graphs were 346 performed in Stata v11.0, R v4.0 or GraphPad Prism (v9.0). P-values <0.05 were considered statistically significant. 347

348

349 Ethics approval and consent to participate

The study received approval from ethics committee of the NIMPE-Ministry of Health, Hanoi, Vietnam (351/QD-VSR and QD2211/QD-BYT); the Institutional Review Board of the Institute of Tropical Medicine, Antwerp, Belgium (937/14); and the ethics committee of Antwerp University Hospital (UZA), Antwerp, Belgium (14/15/183). Written informed consent was obtained from all participants or their respective parents/guardians in case of minors. The trial was registered on ClinicalTrials.gov under identifier NCT02610686.

356 **RESULTS**

357

358 **Patient recruitment and characteristics at baseline**

A total of 480 patients were screened at the different CHC out of which 68 (14.2%) had P.

vivax infection confirmed by LM. Sixty-seven were enrolled and completed CQ treatment

361 (Fig 1). Twenty-seven (40.3%) patients self-presented at Chu R'Cam CHC, whereas the other

362 40 (59.7%) were referred from nearby communes. The age range was 8 to 45 years old and

most patients were male (91%; Table 1). Two thirds of participants reported having had an

episode of malaria in the past year (62.7%).

365

Fever was detected in 56 patients (83.6%) at the time of enrolment, 7 patients (10.4%)366 presented anemia (Hb<11g/dL) and 1 patient was detected with G6PD deficiency. All 367 patients reported headache and fatigue together with other clinical symptoms, most 368 commonly dizziness and chills. Up to 87% of infections carried detectable level of 369 gametocytes by LM (Table 1). Asexual parasite density was significantly correlated with 370 body temperature (ρ =0.435, p<0.001), density of gametocytes (n=58; ρ =0.525, p<0.001) and 371 proportion of ring stages (n=64; ρ =0.431, p<0.001) but did not differ between age groups 372 373 (p=0.971).

374

375 CQ efficacy endpoints

Overall, CQ treatment was well tolerated, with 3 patients reporting moderate adverse effects (dizziness, diarrhea, and abdominal pain). The median CQ dose received by patients was 24.5 mg/kg (IQR 24.0-25.4). Endpoint analysis was conducted using LM data. PCT and parasite clearance half-life (PC_{1/2}) were estimated at 48.3 h (maximum 95.3 h) and 4.1 h (max.13 h),

380	respectively (Table 2). All patients were negative by LM at Day 4. Sixty-six (98.5%) and 65
381	(97.0%) patients completed the 28-day and the 42-day follow-up, respectively (Table 2). At
382	Day 28, the rate of ACPR was 100% (98.5% [66/67] based on ITT analysis), whereas at Day
383	42 the rate of ACPR was 75.4% (73.1% [49/67] based on ITT analysis). Out of 16
384	recurrences, three presented with fever (LCF, days 33-42), while the other 13 were afebrile
385	(LPF, >Day 35). Mean parasitemia at recurrence was 538.7 parasites/µl (95% CI 227.8,
386	1274.0), and was higher in LCF (n=3; 3024.2 parasites/µl [95% CI 1946.9, 4697.6])
387	compared to LPF (n=13; 361.7 [95% CI 143.5, 911.9]; p=0.026). Gametocytes were observed
388	in 6/16 (37.5%) infections at DRec.

389

390 After qPCR correction, parasite clearance rate did not differ significantly from that 391 determined by LM (p=0.338, log-rank; Fig 2A), although the number of Day 3 positives increased to 13.9% (9/65) by qPCR as compared to 3% (2/65) by LM. On the other hand, 392 gametocyte clearance rate was significantly slower by RTqPCR than by LM (p<0.001, log-393 rank; Fig 2B), and 11.3% were found gametocyte-positive on Day 3. Two additional 394 recurrences were detected by molecular methods on Day 42 (total recurrences=18), resulting 395 in a qPCR-corrected ACPR of 73% at the end of the 42-day follow-up (68.7% [46/67] as per 396 397 ITT analysis).

398

All 18 recurrences occurred after day 33 (median 42 days [IQR 35-42]; mean 38.7; range 33-400 43 days) and affected younger individuals (median age 18 years old [IQR 16, 21]), as 401 compared to patients with ACPR (25 years [IQR 20, 28], p=0.002; Table 4). Recurrent and 402 non-recurrent infections did not differ in the CQ dose administered (24.6 mg/kg [24.0, 25.5] 403 *versus* 24.5 mg/kg [IQR 24.0, 25.0]; p=0.787). Blood concentrations of CQ and DCQ at

404	DRec were found to be below 100ng/ml (median 30.3 ng/ml [IQR 15.2, 36.4]; max. value
405	52.3ng/ml) in the 14 patients with valid test result (all Day 7 concentrations were >100ng/ml:
406	502 ng/ml [IQR 358, 601]; n=15). PCT was longer in infections that presented recurrence
407	(n=18; 54.2h [IQR 48.4, 62.0]) compared to those with ACPR (n=46; 47.5h [IQR 36.2, 59.8],
408	p=0.035; Table 4), and a similar trend was observed for $PC_{1/2}$ (recurrent: 4.8h [IQR 4.0, 5.5];
409	ACPR: 4.0h [IQR 3.4, 5.2], p=0.078). Asexual parasitemia at Day 0 was not significantly
410	different between recurrent (n=49; mean 6762.3 p/ul [95% CI 3811.7, 11997.0]) and non-
411	recurrent infections (n=16; 7114.3 p/ul [95% CI 3726.7, 13581.3], p=0.462), and neither was
412	positivity at Day 2 (p=0.409) or Day 3 (p=0.772; Table 4).
413	

414 Genotyping of recurrent infections

Treatment failures were corrected by genotyping approaches and classified as genetically 415 416 homologous or genetically heterologous infections relative to the initial infection at Day 0, using three technical approaches in increasing order of resolution. Initially, Day 0/DRec 417 sample pairs were genotyped at four MS markers by PCR and capillary electrophoresis 418 (Table 3 and Table S3). Overall, 2/18 (11%) samples at Day 0 and 4/15 (27%) at DRec were 419 monoclonal. Fifteen sample pairs had data for at least 2 markers (Table 3). Median COI was 420 421 3 (IQR 2-3) at Day 0 compared to 2 (IQR 1-3) at DRec (p=0.080, signed-rank). Homologous 422 recurrences by MS accounted for 80% (12/15) of total recurrences. In a second step, recurrences were genotyped using a 38-SNP molecular barcode (35). 423

Barcodes were successful in 11 Day 0/DRec sample pairs, although two of them at only 20

and 22 SNP positions, respectively (Table 3 and Data S1). COI was 1 (IQR 1-1) at Day 0 and

426 2 (IQR 1-2) at DRec (p=0.034, signed-rank). Homologous recurrence rate was 55% (6/11).

427 Compared to MS (n=10 pairs), the SNP-barcode identified 4 additional heterologous
428 infections and categorized two MS-heterologous infections as homologous.

429 Finally, samples were subject to WGS aiming for a maximum level of resolution. Fourteen Day 0/DRec DNA sample pairs generated sequencing reads in both samples. Mean 430 sequencing coverage ranged from 1.6–50.1 (overall mean 30.3 ± 14.5) and there was no 431 significant difference in coverage between samples from Day 0 and DRec (p=0.280, paired 432 433 t-test; Table S2). COI was 1 in 58% (7/12) of samples at Day 0 and 73% (8/11) at DRec. WGS analysis of identity-by-state (IBS; *i.e.* number of discordant SNP) identified 60% (6/10) 434 435 of homologous recurrences (Table 3). Compared to MS (n=9 pairs), IBS categorized three 436 originally homologous recurrences as heterologous. WGS data analysis of identity-by-437 descent (IBD; *i.e.* considering inheritance from a common ancestor) identified 80% (8/10) recurrent infections as homologous, all of them with >98% of their genome identical-by-438 descent with the paired Day 0 sample (median 99.7% [IQR 0.3%], n=8). Median IBD found 439 440 between Day 0/DRec pairs (99.6% [IQR 98.4-99.8%], n=10) was significantly higher than 441 the IBD found in all between-patient comparisons (0% [IQR 0-0.60%], n=196, p<0.001, Mann-Whitney U Test), suggesting it is unlikely that high IBD observed is caused by 442 443 independent infections with a closely related clone. Results between IBS and IBD were 444 discordant in 2 out of the 10 sample pairs (patients 022 and 043), which had a considerably high number of discordant SNP by IBS (6.8% and 12.6%) but high IBD proportion (98.1% 445 446 and 99.8%); mean sequencing coverage was >34.2 for both samples and timepoints. Assuming IBD provides the highest level of resolution and most restricted definition of 447 448 homology, the final rate of homologous recurrence (IBD-homologous) in the study was of at least 12% (8/65) out of all patients that completed the 42-day of follow-up, and of at least 449 44% (8/18) out of total recurrences. 450

451

452	Compared to patients with ACPR, patients with IBD-homologous recurrences (n=8) were
453	not different in CQ uptake (24.1 mg/kg [IQR 23.0, 25.2], p=0.565) or parasite density at Day
454	0 (p=0.142; Table 4). However, median PCT among IBD-homologous was significantly
455	longer than in those with ACPR (p=0.019).
456	
457	Drug-resistance characteristics
458	Phenotypic assessment of CQ susceptibility was conducted using the short-term schizont
459	maturation assays at Day 0. A total of 41 cultures were conducted out of which 21 were valid
460	for analysis (51% success rate). The overall CQ IC50 geometric mean was 40.4 nM (95% CI
461	31.5, 51.8; range 10.4-108.0). There were no differences in ex vivo CQ sensitivity between
462	recurrent and non-recurrent infections (Table 4 and Fig 3).

At genetic level, mutations in *pvmdr1* codons F976Y and F1076L were common (30.2% [19/63] for F976Y and 95.2% [60/63] for F1076L) but no differences were found in prevalence of mutations between treatment outcome groups at Day 0 (Table 4). In samples sequenced at DRec (n=10), F976Y and F1076L variants were found in 20% (2/10) and 100% (10/10) of the sequences, respectively.

469

Gene expression of *pvcrt* and *pvmdr1* was determined in all samples with sufficient RNA
quantity at both Day 0 (n=51) and DRec (n=13). At Day 0, median *pvcrt* levels were 2.2-fold
higher in infections that led to recurrence as compared to those with ACPR (p=0.002,
Wilcoxon rank-sum), an increase that was also observed when only IBD-homologous
recurrences were considered (Table 4). No difference between treatment outcome groups at

475 Day 0 was found for *pvmdr1* levels (p=0.138; Table 4). Comparisons at Day 0 were not 476 affected after adjustment by multiple comparisons (Fig 4). We did not find an association between ring-stage proportion and gene expression of either *pvcrt* in linear regression models 477 to suggest there was a potential confounding effect of parasite life-stage on transcript levels 478 (see Fig S3). There was no correlation between parasite ex vivo CQ susceptibility (defined 479 by IC50 values) and gene expression of *pvcrt* (n=13; Spearman's rho=-0.217, p=0.476) or 480 481 *pvmdr1* (n=17; Spearman's rho=-0.120, p=0.646). Parasites collected at DRec showed a wide range of *pvcrt* expression levels (n=9; R=0.39) 482 483 [IQR 0.07, 1.83]), which did not differ significantly from those in the ACPR group 484 (p_{adi}=0.271, rank-sum; Fig 4) or in Day 0 samples with a later recurrence, either in unpaired $(p_{adj}=0.978)$ or in Day0/DRec matched pairs analysis (n=8; ΔR [DRec-Day0]=-0.1 [IQR -0.6, 485 486 0.8], p=1.000, signed-rank test; see Fig S4). Expression of *pvmdr1* was higher at DRec (n=12; R=0.70 [IQR 0.08, 3.09]) as compared to ACPR ($p_{adj}=0.016$; Fig 4), but not compared to Day 487 488 0 samples with a later recurrence, either in unpaired ($p_{adi}=122$) or Day0/DRec matched pairs

489 analysis (n=10; ΔR =0.2 [IQR -0.1, 1.3], p=0.203; Fig S4).

490

491 **DISCUSSION**

492

This study evaluated CQ therapeutic efficacy for uncomplicated *P. vivax* malaria in Gia Lai province, Vietnam. The success rate for *P. vivax* treatment was 100% by Day 28 and 75.4% by Day 42. All recurrences detected by qPCR (n=18) occurred after day 33 in the presence CQ levels below MEC (<100 mg/ml) and were associated with longer PCT of primary infection, younger age, and higher transcript levels of *pvcrt* at baseline. Eighty percent of

recurrences (8/10) with WGS data were homologous to primary infections using IBDanalysis, leading to a homologous recurrence rate at Day 42 of at least 44% (8/18).

500

Among previous CO TES studies conducted in Vietnam that detected early recurrences (*i.e.* 501 502 <Day 28) (20,21,23), only one confirmed recurrent infections (n=3) with blood CQ 503 concentration above MEC in Ouang Nam in 2011 (20). Although the present study was 504 conceived as a continuation of CQR monitoring in Quang Nam province (20), malaria cases 505 rapidly decreased there after 2013, with mostly residual P. vivax by 2015, which was 506 insufficient to conduct classical TES designs due to obvious time and logistic constraints 507 (48). The primary endpoints presented in this study suggest CQ remained largely efficacious in Gia Lai province until 2017, with mostly late recurrences detected after Day 28 in the 508 509 presence of blood CQ concentrations below MEC, similar to findings in the southern province of Binh Phuoc (22). 510

511

Recurrences occurring after Day 28 of follow-up and in the presence of blood CQ 512 concentrations below MEC have generally been classified as relapses (4,49), which is in line 513 with the frequent relapse phenotype of *P. vivax* strains in the study region (*i.e.* mean time-to-514 515 relapse of 41 days (3)). Nevertheless, a thorough revision of *P. vivax* relapses in tropical areas 516 also showed that recrudescent infections of low-grade CQR parasites will become patent at 517 the same time as relapsing infections, due to parasite expansion coincident with the fall in 518 drug levels (7). Some of the findings in the present study undoubtedly suggest that low-grade P. vivax CQR should not be ruled out. 519

First, recurrences had a significantly longer PCT than ACPR infections. The difference in
PCT was independent of parasite densities at Day 0, suggesting that they were not attributable

to an incomplete clearance of a higher parasite inoculum (7). The observation that recurrences occurred in younger individuals (*i.e.* less frequently exposed to *P. vivax* infection throughout life [7, 51], hence with weaker immune response to support drug-mediated clearance) could also have further contributed to the persistence of low-grade CQR parasites. Regardless, given that the median age in both treatment outcome groups falls within early adulthood (18 vs 25 years old) the effect of age, if any, would probably be small.

528 Second, genetic analysis revealed a remarkably high proportion of homologous recurrences 529 using both common microsatellite genotyping (80% rate using 4 MS marker) but also fine-530 scale genomic approaches, which resulted in a minimum of 44% (8/18) homologous 531 recurrence rate with a degree of relatedness to Day 0 infections above 98% IBD. An earlier 532 review of *P. vivax* clinical studies concluded that relapses in endemic areas commonly occur with heterologous genotypes (as over-repeated liver inoculations lead to the accumulation 533 of genetically diverse hypnozoites), whereas homologous relapses are more likely to occur 534 535 either in patients recently treated with PQ (*i.e.* those that cleared pre-existing hypnozoites) 536 or in those living in areas with very little parasite genetic diversity (7). More recently, a study conducted in Cambodia investigated recurrent P. vivax infections among 20 patients 537 reallocated to an area with no malaria transmission, in order to exclude the possibility of 538 539 acquiring new infections(10). Although recurrences were comparable to our study in terms of recurrence time (>Day 33) and blood CQ concentrations (<MEC), they were classified as 540 541 genetically heterologous based on allelic differences by WGS or high-throughput SNP 542 genotyping (6/8), in contrast to the low heterologous rate in our study despite using an IBD approach (2/10). The authors concluded that all recurrences were thus caused by relapses 543 (10). The possibility that IBD-homologous recurrences we identified in Vietnam were also 544 545 caused by relapses (or even reinfections) with an identical parasite genotype cannot be totally

546 excluded, as we could be underestimating the presence of new alleles due to a lower WGS 547 coverage in our study. However, the latter seems unlikely given: i) the excess of genetically 548 identical parasites in recurrent samples observed using IBD (low genome coverage would underestimate relatedness by IBD compared to IBS analysis, which can misclassify unrelated 549 550 parasites as homologous due to sharing of alleles by chance); ii) the fact that the number of 551 genetically different sample pairs remained when only the dominant clones were considered 552 in the Cambodian study (thus increased depth does not explain the differences in 553 heterologous rate between studies); iii) the higher rate of polyclonally among primary 554 infections with a later recurrence (89% [16/18]; mean COI=3 by MS) as compared to 50% 555 (10/20) in Cambodia (suggesting a higher genetic diversity in Vietnam that would increase the chance of detecting heterologous recurrences if those were caused by a relapse; indeed, 556 the very limited use of PQ as radical cure in Vietnam may further favor high hypnozoite 557 diversity in the country (50)). 558

559 Finally, the third finding suggesting some degree of COR is the higher baseline transcript 560 levels of *pvcrt* in recurrent infections compared to patients with ACPR, independently of parasite stage composition (51,52). This suggests that P. vivax parasites expressing higher 561 levels of *pvcrt* may have reduced CQ susceptibility. Data on *pvcrt* expression in response to 562 563 CQ treatment is limited. In line with our results, a previous study in Brazil found increased *pvcrt* (and *pvmdr1*) levels in *P. vivax* parasites with CQR phenotype both at Day0 and at time 564 565 of recurrence (17). A recent study in non-human primates infected with a genetic cross of P. 566 vivax parasites with different CQ responses identified a strong selection of the chromosome 1 region that includes pvcrt, linked to the CQR phenotype and upregulation of pvcrt 567 expression(18), supporting a role of *pvcrt* in the molecular mechanism of CQR. As for 568 *pvmdr1*, increased expression found at DRec (although not confirmed in the matched pairs 569

analysis) could hypothetically reflect a mechanism of drug resistance or be a consequence of an altered membrane transport after drug exposure, but current knowledge of the physiological function of *pvmdr1* is still very limited (53). There is a clear need to further investigate the patterns of *pvcrt* and *pvmdr1* expression in a higher number of ACPR and recurrent samples (both homologous and heterologous) to elucidate their role in CQ susceptibility.

576 Considering a genetically homologous recurrence as a true recrudescence would imply that 577 parasites observed at Day 0 remain in the human host at levels below qPCR detection limit 578 for several weeks while CQ blood concentrations are over MEC. It has been proposed that 579 P. vivax parasites seen in the bloodstream represent only a portion of the total parasite 580 biomass, and that a fraction of parasites may hide in the bone marrow (54–56). Several studies strongly support the role of this tissue as a parasite reservoir, both in human and non-581 human primates (57)(58). An hypothetical scenario could be one in which a sub-populations 582 583 of parasites with higher *pvcrt* expression persist in bone marrow parenchyma where CQ 584 levels are lower, leading to homologous recurrences as soon as drug concentrations decrease 585 significantly below the MEC threshold, furthermore coinciding with the time hypnozoite 586 stages are reactivated producing relapse (7).

587

A limitation of this study was the impossibility to characterize the phenotype of isolates at time of recurrence to provide further evidence of low-grade CQR recrudescence in addition to our findings at the genomic level. Additionally, for the number of samples eligible for *ex vivo* assays or genomic analysis were lower than the total number of patients recruited, a common challenge of *P. vivax* field studies (*i.e.* low parasite density infections and poor adaptation to *ex vivo* conditions). Another difficulty is the intrinsic logistical constraints

594 linked to TES in settings where transmission is being drastically reduced, which questions 595 the feasibility of classical *in vivo* studies under these epidemiological conditions. Such 596 limitation could potentially be overcome once a CQR marker is validated and can be 597 implemented into molecular surveillance, similarly to the ongoing surveillance of *P*. 598 *falciparum* artemisinin resistance in Greater Mekong Subregion based on the *pfkelch-13* gene 599 (59).

600

In conclusion, despite the full efficacy of *P. vivax* CQ treatment at Day 28, we find clinical 601 (PCT), genomic (high rate of IBD homology) and transcriptional (increased *pvcrt* expression) 602 evidence suggesting recurrences after Day 28 can be attributable to low-grade CQR 603 recrudescence rather than genetically homologous relapses of liver hypnozoites. Emergence 604 605 of CQR parasites should be closely monitored. The conclusive identification of a molecular 606 marker is of uttermost importance to unequivocally define *P.vivax* COR, and detect early 607 warning signs of CQR in molecular surveillance studies conducted in endemic areas. The 608 finding that *pvcrt* (and even *pvmdr1*) may play a role in *in vivo* CQ susceptibility deserves further attention. 609

610

611 ACKNOWLEDGEMENTS

612

We sincerely thank all individuals that accepted to enroll in the trial, all staff from Chu
R'Cam CHC and local authorities in Krong Pa district. We are especially grateful to Tran
Tuyet Mai, Nguyen Thi Thuy Duong and Do Manh Ha for their support to field work; and to

Ric Price and Kamala Thriemer (Menzies School of Health Research) for clinical trialprotocol guidelines and helpful discussion.

- 618 The study was funded by Belgium Development Cooperation (DGD) under the Framework
- Agreement Program between DGD and ITM (FA3-III, 2014-2016, FA4 2017-2021). This
- 620 publication uses data from the MalariaGEN SpotMalaria Project, coordinated by the
- 621 MalariaGEN Resource Centre supported by Wellcome (098051, 090770). Both Chloroquine
- and Primaquine were provided at no cost by Sanofi.
- 623

624 AUTHORS CONTRIBUTIONS

625

626 Conceived and designed the study: ERV, NVH, AE, ARU; performed the experiments: ERV,

627 NVH, JHK, NTS, NTTH, NTHN, PG, ES; analyzed the data: ERV, NVH, JHK; contributed

data collection/logistics/materials/analysis tools: NLH, TTM, NTTD, NDL, TTD, NXX, AE;

629 wrote the paper: ERV, JHK, ARU. All authors read and approved the final version of the

manuscript. The authors declare they have no conflicts of interest.

631

630

632 **REFERENCES**

- 633
- World Health Organization. World Malaria Report 2020. 2020. Available from:
 https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report 2020
- 637 2. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the
 638 Era of the Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560–70.
- 639 3. Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global

- 640 epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95(6 Suppl):15–34.
- 4. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of
- 642 chloroquine-resistant Plasmodium vivax: A systematic review and meta-analysis.
- 643 Lancet Infect Dis. 2014;14(10):982–91.
- 644 5. World Health Organization. Methods for surveillance of antimalarial drug efficacy.
- 6452009.Availablefrom:646https://www.who.int/malaria/publications/atoz/9789241597531/en/
- 647 6. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob
- 647 6. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents
 648 Chemother. 2004;48(11):4075–83.
- 649 7. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J.
 650 2011;10(297).
- 8. Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation
 of drug-resistant Plasmodium vivax. Trends Parasitol. 2012; 28(11):522–9.
- 9. Popovici J, Pierce-Friedrich L, Kim S, Bin S, Run V, Lek D, et al. Recrudescence,
- Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine
 Efficacy for Plasmodium vivax Malaria. J Infect Dis. 2019;219(2):315–22.
- Popovici J, Friedrich LR, Kim S, Bin S, Run V, Lek D, et al. Genomic analyses reveal
 the common occurrence and complexity of plasmodium vivax relapses in cambodia.
 MBio. 2018 1;9(1).
- Noulin F, Borlon C, Van Den Abbeele J, D'Alessandro U, Erhart A. 1912-2012: A
 century of research on Plasmodium vivax in vitro culture. Trends Parasitol.
 2013;29(6):286–94.
- Brega S, Meslin B, de Monbrison F, Severini C, Gradoni L, Udomsangpetch R, et al.
 Identification of the Plasmodium vivax mdr- Like Gene (pvmdr1) and Analysis of

- 664 Single-Nucleotide Polymorphisms among Isolates from Different Areas of
 665 Endemicity J Infect Dis. 2005;191(2):272–7.
- 13. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et
- al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association
- with molecular polymorphisms. PLoS One. 2007;2(10):e1089.
- 669 14. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, et al.
- Amplification of pvmdr1 Associated with Multidrug-Resistant Plasmodium vivax. J
 Infect Dis. 2008;198(10):1558–64.
- 15. Silva SR, Almeida ACG, Da Silva GAV, Ramasawmy R, Lopes SCP, Siqueira AM,
- et al. Chloroquine resistance is associated to multi-copy pvcrt-o gene in Plasmodium
 vivax malaria in the Brazilian Amazon. Malar J. 2018;17(1).
- Barnadas C, Ratsimbasoa A, Tichit M, Bouchier C, Jahevitra M, Picot S, et al.
 Plasmodium vivax resistance to chloroquine in Madagascar: Clinical efficacy and
 polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother.
 2008;52(12):4233–40.
- 17. Melo GC, Monteiro WM, Siqueira AM, Silva SR, Magalhães BML, Alencar ACC, et
- al. Expression levels of pvcrt-o and pvmdr-1 are associated with chloroquine
 resistance and severe Plasmodium vivax malaria in patients of the Brazilian Amazon.
- 682 PLoS One. 2014;9(8).
- 18. Sá JM, Kaslow SR, Moraes Barros RR, Brazeau NF, Parobek CM, Tao D, et al.
 Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic
 cross. Nat Commun. 2019;10(1):4300.
- Goldlust SM, Thuan PD, Giang DDH, Thang ND, Thwaites GE, Farrar J, et al. The
 decline of malaria in Vietnam, 1991–2014. Malar J. 2018;17(1):226.

29

- 688 20. Thanh PV, Van Hong N, Van Van N, Louisa M, Baird K, Xa NX, et al. Confirmed
 689 Plasmodium vivax resistance to chloroquine in central Vietnam. Antimicrob Agents
- 690 Chemother. 2015;59(12):7411–9.
- 691 21. Phan GT, De Vries PJ, Tran BQ, Le HQ, Nguyen N V., Nguyen T V., et al. Artemisinin
- 692 or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop Med Int
 693 Heal. 2002;7(10):858–64.
- Thuan PD, Ca NTN, Van Toi P, Nhien NTT, Thanh NV, Anh ND, et al. A randomized
 comparison of chloroquine versus dihydroartemisinin-piperaquine for the treatment of
 plasmodium vivax infection in Vietnam. Am J Trop Med Hyg. 2016;94(4):879–85.
- 697 23. Phong NC, Chavchich M, Quang HH, San NN, Birrell GW, Chuang I, et al.
 698 Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to
 699 chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.
- 700 Malar J. 2019;18(1):10.
- 701 24. National Malaria Control and Elimination Program (NMECP) in Vietnam. Malaria
 702 Report 2014 [Internal Report]. NIMPE; 2015.
- 25. Rovira-Vallbona E, Hong N Van, Kattenberg JH, Huan RM, Hien NTT, Ngoc NTH,
- et al. Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the
 treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam. J
 Antimicrob Chemother. 2020;75(8).
- 707 26. Ministry of Health Vietnam. Guidelines of diagnosis, treatment and prevention of
- malaria disease. 2016. Available from: https://thuvienphapluat.vn/van-ban/The-thao-
- 709 Y-te/Quyet-dinh-4845-QD-BYT-Huong-dan-chan-doan-dieu-tri-benh-Sot-ret-2016-
- 710 321533.aspx
- 711 27. Rosanas-Urgell A, Mueller D, Betuela I, Barnadas C, Iga J, Zimmerman PA, et al.

30

712		Comparison of diagnostic methods for the detection and quantification of the four
713		sympatric Plasmodium species in field samples from Papua New Guinea. Malar J.
714		2010;9:361.
715	28.	Wampfler R, Mwingira F, Javati S, Robinson L, Betuela I, Siba P, et al. Strategies for
716		detection of Plasmodium species gametocytes. PLoS One. 2013;8(9):e76316.
717	29.	Basco LK. Field application of in vitro assays sensitivity of human malaria parasites
718		antimalarial drugs. World Health Organization. World Health Organization; 2007.
719		Available from: https://www.who.int/malaria/publications/atoz/9789241595155/en/
720	30.	WWARN In vitro Module. Preparation of predosed plates. WWARN Procedures.
721		2011. Available from:
722		https://www.wwarn.org/sites/default/files/INV03_PreparationOfPredosedPlates.pdf
723	31.	Woodrow CJ, Dahlström S, Cooksey R, Flegg JA, Le Nagard H, Mentré F, et al. High-
724		Throughput Analysis of Antimalarial Susceptibility Data by the WorldWide
725		Antimalarial Resistance Network (WWARN) In Vitro Analysis and Reporting Tool.
726		Antimicrob Agents Chemother. 2013;57(7):3121-30.
727	32.	Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, et al. Evaluation of
728		Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J
729		Infect Dis. 2009;199(7):1074–80.
730	33.	Hong N Van, Delgado-Ratto C, Thanh PV, Van den Eede P, Guetens P, Binh NTH, et
731		al. Population Genetics of Plasmodium vivax in Four Rural Communities in Central
732		Vietnam. PLoS Negl Trop Dis. 2016;10(2).
733	34.	Van den Eede P, Erhart A, Van der Auwera G, Van Overmeir C, Thang ND, Hung
734		LX, et al. High complexity of Plasmodium vivax infections in symptomatic patients
735		from a rural community in central Vietnam detected by microsatellite genotyping. Am

736 J Trop Med Hyg. 2010;82(2):223–7.

- 737 35. Baniecki ML, Faust AL, Schaffner SF, Park DJ, Galinsky K, Daniels RF, et al.
- 738 Development of a Single Nucleotide Polymorphism Barcode to Genotype
 739 Plasmodium vivax Infections. PLoS Negl Trop Dis. 2015;9(3).
- 740 36. Cowell AN, Loy DE, Sundararaman SA, Valdivia H, Fisch K, Lescano AG, et al.
- 741 Selective whole-genome amplification is a robust method that enables scalable whole-
- 742 genome sequencing of Plasmodium vivax from unprocessed clinical samples. MBio.743 2017;8(1).
- 37. Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina
 sequence data. Bioinformatics. 2014;30(15):2114–20.
- 746 38. Pearson RD, Amato R, Auburn S, Miotto O, Almagro-Garcia J, Amaratunga C, et al.
 747 Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nat
 748 Genet. 2016;48(8):959–64.
- Auburn S, Campino S, Miotto O, Djimde AA, Zongo I, Manske M, et al.
 Characterization of Within-Host Plasmodium falciparum Diversity Using NextGeneration Sequence Data. Snounou G, editor. PLoS One. 2012;7(2):e32891.
- 40. Auburn S, Getachew S, Pearson RD, Amato R, Miotto O, Trimarsanto H, et al.
 Genomic Analysis of Plasmodium vivax in Southern Ethiopia Reveals Selective
 Pressures in Multiple Parasite Mechanisms. J Infect Dis. 2019;220(11):1738–49.
- 41. Henden L. isoRelate. 2016; Available from: https://doi.org/10.5281/zenodo.197857#
- 42. Martinelli A, Hunt P, Fawcett R, Cravo PVL, Walliker D, Carter R. An AFLP-based
- genetic linkage map of Plasmodium chabaudi chabaudi. Malar J. 2005;4(1):11.
- 43. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-
- 759 PCR. Nucleic Acids Res. 2001; 29(9):e45.

760	44.	Golassa L,	Kamugisha E	, Ishengoma D	S, Baraka V	V, Shayo	A, Balin	raine FN,	et a	1
				/ .	/	, , ,	/			

- 761 Identification of large variation in pfcrt, pfmdr-1 and pfubp-1 markers in Plasmodium
- falciparum isolates from Ethiopia and Tanzania. Malar J. 2015;14(1):1–9.
- 45. Lin JT, Patel JC, Kharabora O, Sattabongkot J, Muth S, Ubalee R, et al. Plasmodium
- vivax isolates from Cambodia and Thailand show high genetic complexity and distinct
- patterns of P. vivax multidrug resistance gene 1 (pvmdr1) polymorphisms. Am J Trop
 Med Hyg. 2013;88(6):1116–23.
- Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of
 parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J.
 2011;10:339.
- Pava Z, Handayuni I, Wirjanata G, To S, Trianty L, Noviyanti R, et al. Expression of
 Plasmodium vivax crt-o Is Related to Parasite Stage but. Antimicrob Agents
 Chemother. 2016;60(1):361–7.
- 48. Kattenberg JH, Erhart A, Truong MH, Rovira-Vallbona E, Vu KAD, Nguyen THN, et
- al. Characterization of Plasmodium falciparum and Plasmodium vivax recent exposure
 in an area of significantly decreased transmission intensity in Central Vietnam. Malar
 J. 2018;17(1).
- Taylor AR, Watson JA, Chu CS, Puaprasert K, Duanguppama J, Day NPJ, et al.
 Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat
 Commun. 2019;10(1).
- Tinh TT, Mai DTT, Thieu NQ. Quality of malaria diagnosis and treatment in some
 hospitals in malaria endemic areas (2015-2016). J Malar Parasite Dis Control
 [Vietnam]. 2017;2(98):3–9.
- 783 51. Pava Z, Handayuni I, Wirjanata G, To S, Trianty L, Noviyanti R, et al. Expression of

- Plasmodium vivax crt-o is related to parasite stage but not Ex Vivo chloroquine
 susceptibility. Antimicrob Agents Chemother. 2016;60(1):361–7.
- 52. Kim A, Popovici J, Menard D, Serre D. Plasmodium vivax transcriptomes reveal
 stage-specific chloroquine response and differential regulation of male and female
- 788 gametocytes. Nat Commun. 2019;10(1).
- 53. Dean P, Major P, Nakjang S, Hirt RP, Martin Embley T. Transport proteins of parasitic
 protists and their role in nutrient salvage. Vol. 5, Front Plant Sci. 2014; 5:153.
- 791 54. Markus MB. Biological concepts in recurrent Plasmodium vivax malaria.
 792 Parasitology. 2018; 145(13):1765-1771.
- 55. Mayor A, Alano P. Bone marrow reticulocytes: A Plasmodium vivax affair?. Blood.
 2015; 25(8):1203-5.
- 795 56. Silva-Filho JL, Lacerda MVG, Recker M, Wassmer SC, Marti M, Costa FTM.

Plasmodium vivax in Hematopoietic Niches: Hidden and Dangerous. Trends Parasitol.
2020;36(5):447–58.

- 57. Baro B, Deroost K, Raiol T, Brito M, Almeida ACG, de Menezes-Neto A, et al.
 Plasmodium vivax gametocytes in the bone marrow of an acute malaria patient and
 changes in the erythroid miRNA profile. PLoS Negl Trop Dis. 2017;11(4).
- Soli 58. Obaldia N, Meibalan E, Sa JM, Ma S, Clark MA, Mejia P, et al. Bone marrow is a
 major parasite reservoir in plasmodium vivax infection. MBio. 2018;9(3).
- Noviyanti R, Miotto O, Barry A, Marfurt J, Siegel S, Thuy-Nhien N, et al.
 Implementing parasite genotyping into national surveillance frameworks: Feedback
 from control programmes and researchers in the Asia-Pacific region. Malar J.
 2020;19(1):271.

TABLES

Table 1. Patients characteristics at baseline.

Variable	N=67
Age group:	
years, median (IQR)	22 (18, 26)
>1-15 years, n (%)	6 (9.0)
>15-25 years, n (%)	37 (55.2)
>25 years, n (%)	24 (35.8)
Sex, males (%)	61 (91.0)
Ethnic group, n (%)	
J'Rai	52 (77.6)
Kinh	15 (22.4)
Weight (kg), median (IQR)	52.5 (48, 61)
Had malaria in the previous year, n (%)	42 (62.7)
Took antimalarials in the previous 14 days	0 (0)
G6PD deficiency	1/67 (1.5)
Fever at enrolment (≥37.5°C), n (%)	56 (83.6)
Body temperature:	
All (°C), median (IQR)	38.5 (37.5, 39.5)
Febrile only (°C), median (IQR)	39.0 (38.4, 39.5)
Clinical symptoms:	
Headache, n (%)	67 (100.0)
Fatigue, n (%)	66 (98.5)
Dizziness, n (%)	48 (71.6)
Chills, n (%)	37 (55.2)
Sweats, n (%)	21 (31.3)
Nausea, n (%)	17 (25.4)
Pain, n (%)	6 (9.0)
Vomiting, n (%)	6 (9.0)
Diarrhea, n (%)	3 (4.5)
Hemoglobin (g/dL), median (IQR)	13.5 (12.5, 14.8)
Anemia (Hb <11g/dL), n (%)	7 (10.4)
Parasitological data by LM:	
Asexual parasites/µl, geomean (95% CI)	5992 (4594, 7815)
Ring-stage %, median (IQR)*	75 (43, 91)
Gametocyte prevalence, n (%)	58 (86.6)
Gametocytes/µl, geomean (95% CI)	223 (171, 290)

*N=64.

Hb, hemoglobin; G6PD, glucose-6-phosphate dehydrogenase.

Table 2. Study endpoints.

Endpoints	n/N (%) or median (IQR)
Primary:	
ACPR	
Day 28	66/66 (100.0)
Day 42	49/65 (75.4)
Treatment failures (Day 42):	
LCF	3/65 (4.6)
LPF	13/65 (20.0)
Time to recurrence in days	42 (35, 42)
Secondary:	
PCT, hours (n=66)	48.3 (36.8, 60.1)
PC _{1/2} , hours (n=63)	4.1 (3.5, 5.4)
Patients with asexual parasitemia at:	
Day 1	56/67 (83.6)
Day 2	25/67 (37.3)
Day 3	2/66 (3.0)
Patients with gametocytes at:	
Day 1	29/67 (43.3)
Day 2	8/67 (11.9)
Day 3	0/66 (0)
Severe anemia (Hb<7g/dL; day 7)	0/34 (0)

ACPR, Adequate clinical and parasitological response; LCF, late clinical failure; LPF, late parasitological failure; PCT, parasite clearance time; $PC_{1/2}$, parasite clearance half-life, *i.e.* time to decrease initial parasitemia by half in log-linear phase; Hb, hemoglobin.

Table 3. Genotyping and categorization of recurrent infections. An extended version is provided in Supplemental Materials as TableS4.

	Micros	satellites	SNP barcode		Whole-genome sequencing				
Patient code	Discordant		Discordant		Ι	BS	IBD		
	MS	Туре	SNP	Туре	Discordant SNP	Туре	% IBD	Туре	
003	0/3	homologous	1/38	heterologous	-	-	-	-	
007	0/4	homologous	2/38	heterologous	14.3%	heterologous	35.2%	heterologous	
008	0/4	homologous	0/37	homologous	2.2%	homologous	99.9%	homologous	
010	-	-	1/38	heterologous	-	-	-	-	
018	0/2	homologous	-	-	-	-	-	-	
021	4/4	heterologous	-	-	-	-	-	-	
022	0/4	homologous	0/37	homologous	6.8%	heterologous	98.1%	homologous	
027	0/4	homologous	-	-	2.3%	homologous	99.5%	homologous	
028	-	-	-	-	-	-	-	-	
034	1⁄4	heterologous	0/38	homologous	1.6%	homologous	99.8%	homologous	
037	-	-	-	-	2.0%	homologous	99.7%	homologous	
043	0/3	homologous	1/38	heterologous	12.6%	heterologous	99.8%	homologous	
044	0/3	homologous	-	-	-	-	-	-	
047	1/3	heterologous	0/22	homologous	8.0%	heterologous	32.5%	heterologous	
048	0/3	homologous	0/20	homologous	1.7%	homologous	99.5%	homologous	
050	0/3	homologous	-	-	-	-	-	-	
053	0/4	homologous	0/38	homologous	-	-	-	-	
054	0/4	homologous	5/38	heterologous	2.4%	homologous	100%	homologous	
Homologous rate:		12/15 (80%)		6/11 (55%)		6/10 (60%)		8/10 (80%)	

MS, microsatellites (Pvmsp1F3+MS4+MS10+PvSal1814); IBS, identity-by-state; IBD, identity-by-descent.

		ACPR		All recurrences			IBD-homologous recurrences			
	N	median (IQR) or n (%)	N	median (IQR) or n (%)	<i>P</i> -value	N	median (IQR) or n (%)	<i>P</i> -value		
Age	49	25 (20, 28)	18	18 (16, 21)	0.002	8	19 (18, 26)	0.103		
CQ dose uptake, mg/kg	47	24.5 (24.0, 25.0)	18	24.6 (24.0, 25.5)	0.787	8	24.1 (23.0, 25.2)	0.545		
Parasitological indicators:										
Parasitemia at Day 0 (LM), parasites/µl*	49	5731.8 (4210.8, 7802.2)	16	6762.3 (3811.7, 11997.0)	0.621	8	12415 (5792, 14031)	0.142		
PCT, hours	48	47.5 (36.2, 59.8)	18	54.2 (48.4, 62.0)	0.035	8	60.3 (48.6, 73.0)	0.019		
PC _{1/2} , hours	46	4.0 (3.4, 5.2)	17	4.8 (4.0, 5.5)	0.078	8	4.8 (4.2, 5.7)	0.125		
Positive at Day 2:										
LM	49	16 (32.7)	18	9 (50)	0.193	8	5 (62.5)	0.13		
qPCR	46	19 (41.3)	17	9 (52.3)	0.409	8	5 (62.5)	0.443		
Positive at Day 3:										
LM	49	2 (4.0)	17	0 (0)	1.000	8	0 (0)	1.000		
qPCR	48	7 (14.6)	17	2 (11.8)	1.000	8	1 (12.5)	1.000		
<i>Ex vivo</i> drug sensitivity (Day 0):										
CQ IC50, nM *	13	41.5 (24.4-80.4)	8	38.7 (10.4-108.0)	0.856	5	51.3 (24.3-108.2)	0.301		
Candidate molecular markers of										
CQR (Day 0):										
V076E	17	21(722)	16	10 (62 5)	0.450	6	2(50.0)	0.251		
E1076	47	34(72.3)	10	10(02.3)	1.000	6	5 (50.0) 6 (100)	1.000		
Plot over averagion P	4/	43 (90)	10	13(93.0)	0.002	0 Q	0(100) 0 17 (0 14 0 29)	0.029		
pvcn expression, K	25	0.09 (0.03, 0.22)	10	0.20(0.13, 0.30) 0.17(0.06, 0.47)	0.002	0	0.17 (0.14, 0.38)	0.038		
<i>pvmar1</i> expression, K	55	0.11(0.04, 0.28)	10	0.17 (0.06, 0.47)	0.138	ð	0.09(0.05, 0.35)	0.779		

Table 4. Main parasitological and drug-resistance characteristics of *P. vivax* infections, by treatment outcome at baseline.

*geometric mean (95% CI).

p-values correspond to results of Wilcoxon rank-sum test (for continuous variables) and Chi-square test (for proportions).

ACPR, adequate clinical and parasitological response; LM, light microscopy; CQR, chloroquine resistance; R, relative expression ratio.



Fig 1. Flow chart of patient screening, enrolment, and follow-up. LTFU, loss to follow-up.



Fig 2. Time to parasite clearance. Kaplan-Meier survival curves for total parasite clearance (A) and gametocyte clearance (B). Results are stratified by light microscopy (n=67, blue line) and qPCR (A; n=63, red line) or RTqPCR (B; n=59, red line), respectively. Colored areas indicate 95% confidence intervals. P-values were calculated using log-rank test. One patient with no Day 7 sample by qPCR/RTqPCR was excluded from this analysis.



Fig 3. *Ex vivo* **susceptibility to chloroquine in schizont maturation assays (SMA).** Graph shows results of CQ-IC50 (nM) in Day 0 samples, stratified by treatment outcome. The type of recurrence based on identity-by-descent (IBD) analysis is indicated with colored dots (black, IBD-homologous recurrence; grey, IBD-heterologous recurrence; white, undetermined by WGS). *ACPR, adequate clinical and parasitological response.*



Fig 4. Gene expression of *pvcrt* **and** *pvmdr1***.** Expression ratio R of *pvcrt* (A) or *pvmdr1* (B) relative to reference gene β -tubulin is displayed in log-scale. Samples are stratified by treatment outcome and day of collection. Horizontal lines indicate median and IQR. The type of recurrence based on identity-by-descent (IBD)analysis is indicated with colored dots (black, IBD-homologous recurrence; grey, IBD-heterologous recurrence; white, undetermined by WGS). Adjusted p-values from pairwise Wilcoxon rank-sum test with Benjamini-Hochberg correction for multiple testing are reported. *ACPR, adequate clinical and parasitological response*.

Supplemental Material

Table S1. PCR reaction mixes and thermocycling conditions. medRxiv preprint doi: https://doi.org/10.1101/2021.01.22.21250265; this version posted February 2, 2021. The copyright holder for this preprint (which was not certified by peer, review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A) PCR reaction mixes and the made Gyarlanguage Gianguage Morani Grant and the made Gyarlanguage Morani Gyarlanguage Morani Grant and the made Gyarlanguage Morani Grant and Morani Gyarlanguage Morani G

Gene	Primer sequences	qPCR mix (μl)	Thermocycling conditions		
pvmsp1F3	msp1F3-fwdp:	Hotstart 10x Buffer	2	1x 95°C, 10min	
	5'-GGAGAACATAAGCTACCTGTCC-3'	dNTP mix (20mM)	2	95°C, 15sec	
	msp1F3-revp:	MgCl2 (25 mM)	1.6	25x 59°C, 30sec	
	5'-GTTGTTACTTGGTCTTCCTCCC-3'	Forward Primer (10µM)	0.5	72°C, 30sec	
		Reverse Primer (10µM)	0.5	1x 72°C, 10min	
		Hotstart Taq Polymerase (Qiagen)	0.2		
		H ₂ O Molecular Biology grade	8.2		
		DNA	5		
	msp1F3-fwdn:	Hotstart 10x Buffer	2	1x 95°C, 10min	
	VIC-5'-CAAGCCTACCAAGAATTGATCCCCAA-3'	dNTP mix (20mM)	2	95°C, 15sec	
	msp1F3-revn:	MgCl2 (25 mM)	1.6	25x 59°C, 30sec	
	5'-ATTACTTTGTCGTAGTCCTCGGCGTAGTCC-3' + tail	Forward Primer (10µM)	0.5	72°C, 30sec	
		Reverse Primer (10µM)	0.5	1x 72°C, 10min	
		Hotstart Taq Polymerase (Qiagen)	0.2		
		H ₂ O Molecular Biology grade	8.2		
		Primary PCR product	5		
MS4	MS4-fwd:	Hotstart 10x Buffer	2.5	1x 95°C, 10min	
	PET-5'- CGATTTACTGTTGACGCTGAA-3'	dNTP mix (20mM)	0.5	95°C, 30sec	
	MS4-rev:	Forward Primer (10µM)	2	40x 60°C, 40sec	
	5'-CTGTCTTCAAAGGAACATGCTCGATGA-3'	Reverse Primer (10µM)	2	72°C, 40sec	
		Acetylated BSA (0,1µg/µl)	0.25	1x 72°C, 10min	
		Hotstart Taq Polymerase (Qiagen)	0.2		
		H ₂ O Molecular Biology grade	12.55		
		DNA	5		
MS10	MS10fwd:	Hotstart 10x Buffer	2.5	1x 95°C, 10min	
	FAM-5'-TTATCCCTGCTGGATGTGAA-3'	dNTP mix (20mM)	0.5	95°C, 30sec	
	MS10rev:	Forward Primer (10µM)	2	40x 58°C, 40sec	
	5'-CTGTCTTTCCTTCAGGTGGGACTTGTT-3'	Reverse Primer (10µM)	2	72°C, 40sec	
		Acetylated BSA (0,1µg/µl)	0.25	1x 72°C, 10min	
		Hotstart Taq Polymerase (Qiagen)	0.2		
		H ₂ O Molecular Biology grade	12.55		
		DNA	5		
PvSal1814	PvSal1814-fwd:	Hotstart 10x Buffer	5	1x 95°C, 5min	
	FAM-5'-AAACAGGCATTAGGTTTAAGAGTG-3'	dNTP mix (20mM)	0.5	95°C, 30sec	
	PvSal1814-rev:	Forward Primer (10µM)	1	40x 54°C, 40sec	
	CAGTGGCTTCTTCTTTAGTGG	Reverse Primer (10µM)	1	72°C, 40sec	
		acetylated BSA (0,1µg/µl)	0	1x 72°C, 8min	
		Hotstart Taq Polymerase (Qiagen)	0.2		
		H ₂ O Molecular Biology grade	32.3		
		DNA	10		

B) PCR reaction mixes and thermocycling conditions for *pvmdr1* genotyping medRxiv preprint doi: https://doi.org/10.1101/2021.01.22.21250265; this version posted February 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Gene	Primer sequences			conditions
pvmdr1	GolPvmdr-1 OF	5X Buffer	10	1x 95°C, 5min
	5'-CGCCATTATAGCCCTGAGCA-3'	MgCl2 (25 mM)	5	95°C, 15sec
	GolPvmdr-1 OR	dNTP mix (20mM)	0.5	33x 55°C, 30sec
	5'-TCTCACGTCGATGAGGGACT-3'	Forward Primer (10µM)	1	72°C, 1min
		Reverse Primer (10µM)	1	1x 72°C, 7min
		GoTaq Polymerase (Promega)	0.25	
		H ₂ O Molecular Biology grade	27.25	
		DNA	5	
	Lin-mdr1_Fw	Buffer	10	1x 95°C, 5min
	5'-ATAGTCATGCCCCAGGATTG-3'	MgCl2 (25 mM)	5	95°C, 15sec
	Lin-mdr1_Rev	dNTP mix (20mM)	0.5	33x 55°C, 30sec
	5'-CCTTTCGAAGGACAGCTTTG-3'	Forward Primer (10µM)	1	72°C, 1min
		Reverse Primer (10µM)	1	1x 72°C, 7min
		GoTaq Polymerase (Promega)	0.25	
		H ₂ O Molecular Biology grade	31.25	
		Primary Product	1	

Data S1 (Excel [S1_Data_GRC.xlsx]). Genetic Report Card (SpotMalaria). The dataset contains drug-resistance genotypes as well as the SNP barcode (Sheet A). An explanatory table with detail of sequenced positions and reference/mutant codon is provided in Sheet B.

		Day 0		Day of recurrence						
Patient code	parasites/µl	coverage (mean X ± SD)	% missing positions	parasites/µl	coverage (mean X ± SD)	% missing positions				
007	41506	41.2 ± 52	0.8%	769	21.4 ± 33	4.4%				
008	6068	27.6 ± 51	13.8%	3428	45.0 ± 43	0.4%				
010	5431	6.8 ± 11	0.9%	212	1.6 ± 15	88.7%				
018	2408	25.5 ± 37	2.9%	103	3.3 ± 22	81.9%				
022	13430	38.9 ± 54	1.6%	444	44.0 ± 46	0.4%				
027	5517	37.1 ± 57	4.6%	3268	42.2 ± 42	0.4%				
034	4010	42.1 ± 56	2.1%	1536	45.5 ± 47	0.4%				
037	11401	38.5 ± 55	2.5%	310	37.5 ± 41	0.6%				
043	55892	42.7 ± 39	0.3%	7477	34.2 ± 40	0.8%				
044	274	46.4 ± 51	0.6%	68	2.5 ± 9	48.6%				
047	4927	25.0 ± 55	27.8%	91	35.0 ± 39	0.6%				
048	13965	50.1 ± 47	0.3%	856	16.9 ± 41	35.5%				
053	11262	8.6 ± 40	81.0%	2469	21.8 ± 52	34.4%				
054	14096	32.3 ± 50	4.0%	440	35.7 ± 55	3.9%				
All		33.1 ± 47	10.2%		27.6 ± 38	21.5%				



Fig S1. Distribution of discordant SNPs by whole-genome sequencing. The proportion of discordant SNPs was determined by calculating the Prevosti distance between all pair-wise comparisons (*i.e.* number of allelic differences/number of possible differences) using the R-package *poppr* (https://cran.r-project.org/web/packages/poppr/index.html). Due to the high likelihood of multiclonal infections in *P. vivax*, distances were fitted as the sum of four Gaussian distributions using the R-package *mixtools* (https://cran.r-project.org/web/packages/mixtools/index.html). The distribution with the lowest proportion of discordant SNPs (red line) was used to define the threshold (mean plus 3x the standard deviation for that distribution) of homologous recurrence for identify-by-state (IBS) analysis.



Fig S2. qPCR standard curves for *pvcrt*, *pvmdr1* and β -tubulin. Standard curves were prepared using 10-fold serial dilutions of dsDNA fragments covering the targeted region in each gene of interest (range 4000000-4 copies/µl). Amplification efficiencies calculated from cycle threshold (Ct) *versus* dsDNA copy number (log transformed) plots were 1.88, 1.90 and 1.84 for *pvcrt*, *pvmdr1* and β -tubulin, respectively.

Table S3. Microsatellites genotyping. Results of allele calling using Genetools software. Shared alleles between

medRxiv preprint doi: https://doi.org/10.1101/2021.01.22.21250265; this version posted February 2, 2021. The copyright holder for this preprint sample patient was you candid by prefective sector of the authority mater, who had granted means to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Patient code	Day	PvMSP1.F3					MS4		M	<u>510</u>	PvSal1814						
		Allele1		A 11e1e3					Allele1		Allele1		Allele3			Allele6	
003	Dav0	264	313	Alleles	Allele4	Alleles	195	198	216	Allelez	528	543	558	Allelet	Alleles	Alleleo	
	DRec	264	010				170	198	210	1	528	543					
007	Dav0	229		264	278	313	198	201	201	207	599	614	629				
	DRec		259			313		201	201		599	614	629				
008	Day0	276					195		201		563	578					
	DRec	276	325				195		201		563	578					
010	Day0	259	306				204		213								
010	DRec																
018	Day0	259	264	316			198	201	204	213	510	525	540				
018	DRec	259							204								
021	Day0	253		300				204	195					573	588	603	
021	DRec		259				201			207	528	543	558				
022	Day0	219	278	327	-		198		195	-	599	614	629	-			
022	DRec		278				198		195		599						
027	Day0	-		325	374	_	201		198	-	555	584	599	-			
027	DRec	147	197		374		201		198		555	584	599				
028	Day0	147	197	325	374		201		198								
028	DRec																
024	Day0	325					201		198			581		596			
034	DRec	325					201		198		555		584				
037	Day0	259					201		201								
037	DRec																
043	Day0	264	272	ļ					204		555	569	584				
043	DRec		272				198		204				584	614			
044	Day0	264					204		210		584	599	614	-			
044	DRec	264		1					210		584	599	614				
047	Day0	253	264				195	201	207		599						
017	DRec	253	264					201	204								
048	Day0	264					223		201								
0-10	DRec	264					223		201		599		T				
050	Day0	264	-				198		213	-	620	635	-				
	DRec	264							213		620						
053	Day0	258					201		201			573	588		-		
	DRec	258					201		201		558	573	588	603			
054	Day0	250	ļ				213		204	4	620	635	4				
	DRec	250					213		204		620	635					

 Table S4. Genotyping and categorization of recurrent infections.

Patient code	Parasite density by LM (p/µl)		Microsatellites					SNP barcode				Whole-genome sequencing						
			COI		Discondont		С	COI			СОІ		IBS		IBD			
	Day0	DRec	Day0	DRec	MS	Туре	Day0	DRec	SNP	Туре	Day0	DRec	Disc. SNP	Туре	% IBD	Туре		
003	3470	0	3	2	0/3	homologous	1	1	1/38	heterologous	-	-	-	-	-	-		
007	41506	769	4	3	0/4	homologous	2	1	2/38	heterologous	>1	>1	14.3%	heterologous	35.2%	heterologous		
008	6068	3428	2	2	0/4	homologous	1	1	0/37	homologous	1	1 1 2.2% homologous		99.9%	homologous			
010	5431	212	2	-	-	-	1	2	1/38	heterologous			-	-	-	-		
018	2408	103	3	1	0/2	homologous	2	-	-	-	>1 -		-	-	-	-		
021	3369	1225	3	3	4/4	heterologous	2	-	-	-	-	-	-	-	-	-		
022	13430	444	3	1	0/4	homologous	1	2	0/37	homologous	1	>1	6.8%	heterologous	98.1%	homologous		
027	5517	3268	3	3	0/4	homologous	1	-	-	-	1	1	2.3% homologous		99.5%	homologous		
028	6849	24	4	-	-	-	1	-	-	-	-	-			-	-		
034	4010	1536	2	2	1/4	heterologous	1	2	0/38	homologous	1 1 1.6% homolo		homologous	99.8%	homologous			
037	11401	310	1	-	-	-	1	-	-	-	1	1 1 2.0% homologous		99.7%	homologous			
043	55892	7477	3	2	0/3	homologous	1	2	1/38	heterologous	>1	>1 1 12.6% heterologous		99.8%	homologous			
044	274	68	3	3	0/3	homologous	-	2	-	-	>1	>1		-	-			
047	4927	91	2	2	1/3	heterologous	2	2	0/22	homologous	>1	>1	8.0%	heterologous	32.5%	heterologous		
048	13965	856	1	1	0/3	homologous	1	2	0/20	homologous	1	1 1 1.7%		homologous	99.5%	homologous		
050	5852	0	2	1	0/3	homologous	1	-	-	-			-	-	-	-		
053	11262	2469	2	4	0/4	homologous	1	2	0/38	homologous	-	1	-	-	-	-		
054	14096	440	2	2	0/4	homologous	1	2	5/38	heterologous	1	1	2.4%	homologous	100%	homologous		
Homologous recurrence rate:			12/15 (80%)							6/11 (55%)	6/10 (60%)					8/10 (80%)		
LM, light identity-b	LM, light microscopy; DRec, samples at day of recurrence; COI, complexity of infection; MS, microsatellites (Pvmsp1F3+MS4+MS10+PvSal1814); IBS, identity-by-state; IBD, identity-by-descent																	

809 51



Fig S3. Gene expression of *pvcrt* and *pvmdr1* and proportion of ring-stages in infections at **Day 0.** Gene expression ratios (R) of *pvcrt* (A) and *pvmdr1* (B) relative to reference gene β -*tubulin* are displayed in log-scale (y axis). Linear regression was fitted to data (black line with standard error bounds in grey) did not show an association between R and ring-stage percentage (*pvcrt*: coef.=-0.0003, p=0.886; *pvmdr1*: coef.=-0.001, p=0.655).



Fig S4. Gene expression of *pvcrt* **and** *pvmdr1* **in Day 0/DRec paired samples.** Differences in gene expression ratio R between infections at DRec and paired infections at Day 0 are shown for both *pvcrt* (A) and *pvmdr1* (B). Type of recurrences based on identity-by-descent (IBD) analysis is shown with coloured bars (black, IBD-homologous recurrence; grey, IBD-heterologous recurrence; white, undetermined by WGS).